Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | NMT1 | P30419 | 5/20 | 0.49 |
| ▸ | NMT2 | O60551 | 4/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29943324 | 1.00 | GSR (0.50) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL29630424 | 1.00 | GSR (0.50) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL30581338 | 1.00 | GSR (0.50) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL30039547 | 0.98 | GSR (0.51) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL30277638 | 0.98 | GSR (0.51) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL30881170 | 0.97 | GSR (0.50) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL30881181 | 0.97 | GSR (0.50) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL24141455 | 0.97 | GSR (0.53) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL30943792 | 0.97 | GSR (0.53) | GSRNMT1NMT2FOLH1DPP8 | |
| SCHEMBL29465874 | 0.97 | GSR (0.53) | GSRNMT1NMT2FOLH1DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | GSR 1035/4885NMT1 957/4885NMT2 1174/4885 |
| US-12370255-B2 | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | MYD88, ICOS, CD4 | GSR 4158/4885NMT1 1474/4885NMT2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.